Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118112 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL15521126 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL31248559 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8227161 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29352034 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL20592813 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL20592811 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29759385 | 0.94 | MDM2 (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL29493132 | 0.92 | MDM2 (0.53) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL8226910 | 0.92 | MDM4 (0.50) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041441-A | Synthesis method of daptomycin | 申联生物医药（上海）股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-111228508-B | Multi-target anti-tumor polypeptide drug conjugate and preparation method and application thereof | 暨南大学 | 2023-02-17 | — | — | CN | claimed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4661891-A2 | PEPTIDES FOR TREATING NEUROLOGICAL DISORDERS | Creative Bio-Peptides Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3071702-B1 | SYNTHESIS OF L-NUCLEIC ACIDS BY MEANS OF AN ENZYME | APTARION BIOTECH AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250195602-A1 | Compositions and Methods for Treating Neuropathy | CREATIVE BIO-PEPTIDES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250154197-A1 | LIPOLYTIC PEPTIDES | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2025-05-15 | — | — | US | disclosed |
| EP-4547337-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | Sanofi (FR) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024003313-A9 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025051920-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR INHIBITORS | SANOFI (FR) | 2025-03-13 | — | — | WO | disclosed |
| CN-108794422-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-112500457-B | Dual-targeting FOXM1/CDK1 anti-tumor polypeptide | 长沙新生康源生物医药有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-108164474-B | 1,2,4- diazole derivatives as immunomodulators | 奥瑞基尼探索技术有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022082006-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022075974-A1 | CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220024882-A1 | NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | MDM4 4874/4885TP53 2182/4885CASP3 1790/4885 |
| US-20220024882-A1 | NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF | CD74, MICA, CD2BP2 | MDM4 1065/4885TP53 4/4885CASP3 4252/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM4 3817/4885TP53 1733/4885CASP3 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.